Zev Wainberg, MD, Oncology, Santa Monica, CA, Ronald Reagan UCLA Medical Center

ZevAryehWainbergMD

Oncology Santa Monica, CA

Hematologic Oncology

Assistant Professor, Medicine, UCLA School of Medicine

Dr. Wainberg is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Wainberg's full profile

Already have an account?

Education & Training

  • UCLA Medical Center
    UCLA Medical CenterFellowship, Hematology/Oncology, 2003 - 2006
  • Albert Einstein College of Medicine
    Albert Einstein College of MedicineResidency, Internal Medicine, 2000 - 2003
  • Tel Aviv University Sackler
    Tel Aviv University SacklerClass of 2000

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2003 - 2023
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Efficacy and Safety of Pembrolizumab or Pembrolizumab plus Chemotherapy vs Chemotherapy Alone for Patients with First-Line, Advanced Gastric Cancer  
    Al Benson, Zev A Wainberg, JAMA Oncology

Lectures

  • First-line durvalumab + monalizumab, mFOLFOX6, and bevacizumab or cetuximab for metastatic microsatellite-stable colorectal cancer (MSS-CRC). 
    ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/25/2020
  • Efficacy of pembrolizumab (pembro) monotherapy versus chemotherapy for PD-L1–positive (CPS ≥10) advanced G/GEJ cancer in the phase II KEYNOTE-059 (cohort 1) and phase ... 
    ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/23/2020
  • Efficacy and safety of pembrolizumab (pembro) alone or in combination with chemotherapy (chemo) in patients (pts) with advanced gastric or gastroesophageal (G/GEJ) can... 
    2019 ASCO Annual Meeting - 6/1/2019
  • Join now to see all

Press Mentions

  • Dr. Wainberg on Impact of PD-L1 Status in Gastric/GEJ Cancer Treatment
    Dr. Wainberg on Impact of PD-L1 Status in Gastric/GEJ Cancer TreatmentJanuary 25th, 2020
  • Ipsen and Servier Announce Initial Phase 1/2 Clinical Data Evaluating Liposomal Irinotecan (ONIVYDE®) as an Investigational First-Line Treatment for Metastatic Pancreatic Cancer at ESMO 21st World Congress on Gastrointestinal Cancer
    Ipsen and Servier Announce Initial Phase 1/2 Clinical Data Evaluating Liposomal Irinotecan (ONIVYDE®) as an Investigational First-Line Treatment for Metastatic Pancreatic Cancer at ESMO 21st World Congress on Gastrointestinal CancerJuly 5th, 2019
  • Patients with Rare Digestive Tract Cancers Respond to New Drug Combination
    Patients with Rare Digestive Tract Cancers Respond to New Drug CombinationNovember 19th, 2018
  • Join now to see all

Hospital Affiliations